Tech Company Financing Transactions

Pulmatrix Funding Round

5AM Ventures, Arch Venture Partners and Novartis BioVenture Fund participated in a $14 million Series B venture round for Pulmatrix. The round was announced on 8/15/2011.

Transaction Overview

Company Name
Announced On
8/15/2011
Transaction Type
Venture Equity
Amount
$14,000,000
Round
Series B
Investors

5AM Ventures (Scott Rocklage)

Arch Venture Partners (Steven Gillis)

Novartis BioVenture Fund (Lauren Silverman)

Polaris Partners (Terry McGuire)

Proceeds Purpose
Proceeds from the financing will enable Pulmatrix to accelerate its lead iCALM drug candidate, PUR118, through Phase 2A efficacy studies in two diseases, chronic obstructed pulmonary disease (COPD) and cystic fibrosis (CF).

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
99 Hayden Ave. 390
Lexington, MA 02421
USA
Email Address
Overview
Pulmatrix Inc. is a pharmaceutical company developing inhalable aerosols and enabling technologies that help control respiratory infectious disease and human-source airborne contamination.
Profile
Pulmatrix LinkedIn Company Profile
Social Media
Pulmatrix Company Twitter Account
Company News
Pulmatrix News
Facebook
Pulmatrix on Facebook
YouTube
Pulmatrix on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Ted Raad
  Ted Raad LinkedIn Profile  Ted Raad Twitter Account  Ted Raad News  Ted Raad on Facebook


 

 

Browse more venture capital transactions:

Prev: 8/15/2011: LendKey venture capital transaction
Next: 8/15/2011: Buddy Media venture capital transaction

 

Share this article

 


About Database of VC Transactions

We do our best to report on funding rounds that are announced publicly. All VC database entries reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary